United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $569.28, for a total transaction of $5,408,160.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $23,063,240.64. The trade was a 19.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

United Therapeutics Price Performance

United Therapeutics stock opened at $577.63 on Tuesday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $607.89. The stock has a market capitalization of $25.32 billion, a P/E ratio of 20.70, a P/E/G ratio of 1.65 and a beta of 0.75. The firm’s 50-day moving average is $518.73 and its two-hundred day moving average is $486.05.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.19 earnings per share. As a group, analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on UTHR. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Cantor Fitzgerald upped their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. HC Wainwright increased their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $601.50.

Institutional Trading of United Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its holdings in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. Darwin Global Management Ltd. purchased a new position in shares of United Therapeutics in the 3rd quarter worth about $317,617,000. Norges Bank acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $293,418,000. Avoro Capital Advisors LLC lifted its stake in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.